PH24467A - Synergistics interplay of lymphokines and dsrnas - Google Patents

Synergistics interplay of lymphokines and dsrnas

Info

Publication number
PH24467A
PH24467A PH36569A PH36569A PH24467A PH 24467 A PH24467 A PH 24467A PH 36569 A PH36569 A PH 36569A PH 36569 A PH36569 A PH 36569A PH 24467 A PH24467 A PH 24467A
Authority
PH
Philippines
Prior art keywords
lymphokines
dsrnas
dsrna
human
interplay
Prior art date
Application number
PH36569A
Other languages
English (en)
Inventor
William A Carter
Original Assignee
Hem Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hem Res Inc filed Critical Hem Res Inc
Publication of PH24467A publication Critical patent/PH24467A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Plant Substances (AREA)
PH36569A 1987-03-03 1988-02-29 Synergistics interplay of lymphokines and dsrnas PH24467A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2136887A 1987-03-03 1987-03-03

Publications (1)

Publication Number Publication Date
PH24467A true PH24467A (en) 1990-07-18

Family

ID=21803798

Family Applications (1)

Application Number Title Priority Date Filing Date
PH36569A PH24467A (en) 1987-03-03 1988-02-29 Synergistics interplay of lymphokines and dsrnas

Country Status (19)

Country Link
EP (1) EP0281380B1 (fr)
JP (1) JPH0713024B2 (fr)
KR (1) KR960008009B1 (fr)
CN (1) CN1054509C (fr)
AT (1) ATE130760T1 (fr)
AU (2) AU1256588A (fr)
CA (1) CA1336810C (fr)
DE (1) DE3854726T2 (fr)
DK (1) DK113188A (fr)
ES (1) ES2082749T3 (fr)
FI (1) FI880961A7 (fr)
IE (1) IE75895B1 (fr)
IL (1) IL85603A (fr)
NO (1) NO880946L (fr)
NZ (1) NZ223720A (fr)
PH (1) PH24467A (fr)
PT (1) PT86879B (fr)
RU (1) RU1836103C (fr)
ZA (1) ZA881512B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA881639B (en) * 1987-03-23 1989-02-22 Hem Res Inc Treatment of human viral infection by dsrna combined with viral inhibitors
ES2076259T3 (es) * 1989-06-30 1995-11-01 American Cyanamid Co Metodo para el tratamiento de enfermedades infecciosas activando celulas fagociticas en animales.
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
FR2768344B1 (fr) * 1997-08-26 2001-02-16 Scras Produit comprenant au moins un arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique dans le traitement d'une maladie virale
FR2768345B1 (fr) * 1997-09-17 2001-05-04 Scras Produit comprenant au moins un arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique dans le traitement d'une maladie virale, notamment d'une hepatite virale
FR2766715B1 (fr) * 1997-08-04 2001-02-16 Scras Produit comprenant au moins de l'arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique simultanee, separee ou etalee dans le temps, dans le traitement d'une maladie virale
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
CN101818145A (zh) 1998-03-20 2010-09-01 联邦科学和工业研究组织 控制基因表达
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US20020132257A1 (en) 2001-01-31 2002-09-19 Tony Giordano Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
WO2006054129A1 (fr) * 2004-11-19 2006-05-26 Institut Gustave Roussy Traitement ameliore du cancer par arn double brin
EP2116602A1 (fr) 2008-05-07 2009-11-11 Institut Gustave Roussy Combinaison de produits pour traiter le cancer
WO2011109833A2 (fr) 2010-03-05 2011-09-09 President And Fellows Of Harvard College Compositions de cellules dendritiques induites et utilisations associées
CN106794246B (zh) 2014-08-08 2021-10-15 OncoQuest制药有限公司 肿瘤抗原特异性抗体和tlr3刺激以增强检查点干扰癌症疗法的性能
TW202308629A (zh) 2021-04-28 2023-03-01 法商Ｅｎｙｏ製藥公司 使用fxr激動劑作為組合治療以增強tlr3激動劑之療效

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0113162B1 (fr) * 1982-09-16 1989-07-19 Hem Research, Inc. Effet antinéoplastiques des acides ds-ribonucléiques sur les cellules des tumeurs
CA1326450C (fr) * 1985-08-26 1994-01-25 William A. Carter Modulation des manifestations associees au virus du sida au moyen d'arn a double brin

Also Published As

Publication number Publication date
IL85603A (en) 1993-05-13
EP0281380A3 (en) 1989-09-27
AU1256588A (en) 1988-09-01
NO880946L (no) 1988-09-05
CN1054509C (zh) 2000-07-19
PT86879B (pt) 1992-05-29
EP0281380A2 (fr) 1988-09-07
JPS63295514A (ja) 1988-12-01
DE3854726T2 (de) 1996-07-25
RU1836103C (ru) 1993-08-23
NO880946D0 (no) 1988-03-03
FI880961L (fi) 1988-09-04
KR880010776A (ko) 1988-10-24
IL85603A0 (en) 1988-08-31
AU1618992A (en) 1992-08-06
NZ223720A (en) 1991-07-26
IE880588L (en) 1988-09-03
DE3854726D1 (de) 1996-01-11
PT86879A (pt) 1988-04-01
IE75895B1 (en) 1997-09-24
ATE130760T1 (de) 1995-12-15
CN1032296A (zh) 1989-04-12
ES2082749T3 (es) 1996-04-01
JPH0713024B2 (ja) 1995-02-15
FI880961A0 (fi) 1988-03-02
FI880961A7 (fi) 1988-09-04
ZA881512B (en) 1988-11-30
CA1336810C (fr) 1995-08-29
DK113188A (da) 1988-09-04
KR960008009B1 (ko) 1996-06-19
DK113188D0 (da) 1988-03-02
EP0281380B1 (fr) 1995-11-29

Similar Documents

Publication Publication Date Title
EP0281380A3 (en) Synergistic interplay of lymphokines and dsrnas
ATE73347T1 (de) Antivirales immunotherapeutisches mittel und dessen herstellung.
NZ226005A (en) Covalent conjugates of a human cytokine and a human immunoglobulin, processes for their manufacture and pharmaceutical compositions thereof
PH23333A (en) Treatment of human viral infections by dsrna combined with viral inhibitors
IL78553A (en) Therapeutic compositions of phosphonylmethoxyalkyl adenines
ATE190064T1 (de) Kombination therapeutische nukleoside mit weiteren therapeutisch wirksamen komponenten.
UA29429C2 (uk) Фармацевтична композиція для лікування вірусних інфекцій, спосіб отримання композиції, спосіб лікування або профілактики віл-інфекції у людини
BG100599A (en) Antiviral form and therapeutical method
ES2036526T3 (es) Composiciones de interferon.
BR9007741A (pt) Protecao contra estados de choque subsequentes a lesoes por rnas de duplo filamento
EP0325018A3 (fr) RNase L inhibiteur comme marqueur pour des infections virales
EP0294538A3 (en) Use of nigericin in the treatment of viral diseases
DE69106877D1 (de) Aus blaualgen hergestellte biologisch aktive verbindungen.
MY111746A (en) Therapeutic nucleosides.
EP1013763A4 (fr) INTERLEUKINE 18 CANINE, INTERLEUKINE-1 $g(b)-CONVERTASE CANINE, SEQUENCES D'ADN CODANT CETTE ENZYME, PROCEDE DE PRODUCTION DE L'INTERLEUKINE 18, ET REMEDES CONTRE LES MALADIES IMMUNOLOGIQUES CHEZ LE CHIEN
Kohl Additive effects of acyclovir and immune transfer in neonatal herpes simplex virus infection in mice
DE3462891D1 (en) New pyrimidine derivatives endowed with antiviral activity
EP0668771A4 (fr) Traitement des maladies autoimmunes par induction d'une tolerance des cellules, des tissus et des organes.
SU1727820A1 (ru) Способ стимул ции сперматогенеза у быков
EP0343258A4 (fr) Agent de prophylaxie et de traitement de maladies provoquees par des infections virales.
ES2007094A6 (es) Procedimiento para la preparacion de 3 -c- ciano-2,3 -didesoxinucleosido.
JO1708B1 (en) The use of trinitrobenzene or cochineal acid in the treatment of cancer or genital diseases
ZA881639B (en) Treatment of human viral infection by dsrna combined with viral inhibitors